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Introduction
Poly(ADP-ribose) polymerase-2 (PARP2, ARTD2) is a member of the PARP family [1, 2] . PARP2 binds to DNA strand breaks or RNA species [3] [4] [5] [6] where it is activated. Active PARP2 cleaves nicotinamide-adenine dinucleotide (NAD + ) to nicotinamide and ADP-ribose, and forms poly(ADP-ribose) polymers (PAR) on acceptor proteins [7] . PARylation often changes the biochemical properties of proteins [8, 9] . PARP2 is responsible for 10-15% of total cellular PARP activity; the remaining activity is mostly due to PARP1 [10, 11] .
Although PARP2 was originally described as a DNA repair/maintenance enzyme [10, 12] , recent studies have widened the scope of its biological roles [8, 9] . Importantly, PARP2
modulates transcription [13, 14] through interactions with numerous transcription factors (PPARs, TTF1, ERα, LXRs, FXRs) [15] [16] [17] . Changes in transcription are major drivers behind PARP2-mediated phenotypes [11, 14, 16, [18] [19] [20] [21] [22] [23] [24] .
PARP2 was shown to be involved in metabolic regulation, including lipid metabolism (reviewed in [25, 26] ). The observation that PARP2 was a positive cofactor of PPARγ and facilitated fat accumulation in white adipose tissue (WAT) [15] demonstrated the role of PARP2 in lipid metabolism for the first time. The deletion of PARP2 disrupts lipid deposition in WAT [15] . However, in PARP2 knockout mice, no atopic lipid is deposited in the liver or skeletal muscle [18] , probably due to increased lipid oxidation, which is detectable at the organismal level as decreased respiratory quotient [18] . Increased lipid oxidation stems from the induction of sirtuin-1 (SIRT1) expression and activity, resulting in mitochondrial biogenesis in the skeletal muscle and liver [18, 21] .
PARP2 also impacts another arch of lipid metabolism through cholesterol biosynthesis and lipoprotein metabolism. PARP2 is a repressor of sterol regulatory element binding protein-1 (SREBP1) expression [14] . In the absence of PARP2, SREBP1 expression and activation increase in the liver, culminating in increased hepatic cholesterol content [14] .
Interestingly, while the enterohepatic circulation of cholesterol does not change in PARP2
-/-mice, the systemic circulation of cholesterol is impaired, marked by lower high-density lipoprotein levels through decreases in hepatic ATP-binding cassette sub-family A Member 1 (ABCA1) expression [14] .
In addition to having these functions, PARP2 had been associated with lipid metabolism in a genome-wide association study [27] , suggesting that there might be other physiologically relevant PARP2-mediated changes in lipid metabolism. Skeletal muscle is a major energy expender in humans and is strongly affected by changes in PARP2 expression [18] , which prompted us to perform a wide-scale assessment of PARP2-mediated changes in skeletal muscle lipid metabolism.
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Results
The silencing or deletion of PARP2 leads to characteristic changes in the lipidome
As a first step, we validated our models by assessing PARP2 expression in PARP2 knockout mice [28] and in C2C12 cells in which PARP2 was silenced by lentiviral transduction of an shRNA construct [18] (Fig. 1A, Fig. S1 ). We performed a mass spectrometry-based lipidomic screening to detect the lipids involved in cell membrane synthesis in the skeletal muscle of PARP2 +/+ and PARP2 -/-mice, as well as in scPARP2 and shPARP2 transfected cells. When we subjected the results to orthogonal partial least squares discrimination analysis (OPLS-DA), both scPARP2 and shPARP2 C2C12 cells and skeletal muscle samples from PARP2 +/+ and PARP2 -/-mice were clearly separated (Fig. 1B) .
Validation of the model was performed by permutation tests (n = 1000), which returned good predictability: Q2 = 0.84 (p = 0.05) for cells and Q2 = 0.57 (p = 0.002) for skeletal muscles.
These data suggest deep and characteristic changes in the lipidome due to inhibition of
PARP2.
The silencing of PARP2 leads to higher muscular cholesterol and anabolic steroid content As a next step, we compared the steady-state gene expression profile of C2C12 cells transfected with scPARP2 or shPARP2 to provide an explanation for the changes in Figure   1 . The analysis revealed the dysregulation of 756 genes, of which 429 were downregulated and 327 were upregulated. Gene ontology analysis of the hits revealed the dysregulation of genes involved in muscular function and metabolism ( Fig. 2A, Table 1 ). Among these genes, we identified increases in the expression of Tnn1, Tnnc, and Tnnt3, which are markers of oxidative, type I, slow-twitch fibers in shPARP2 cells. As the deletion of PARP2 is linked to increased proportions of type I fibers [18] , increased expression of Tnn1, Tnnc, and Tnnt3 validates our findings. Among the metabolic genes, we identified several [29] lipid metabolism-related genes, of which 22 were upregulated ( Fig. 2A, Table 1 ).
A thorough analysis of the lipid metabolism genes revealed that Srebp1, Srebp2, and several of their downstream targets (Cyp7a1, Fdps, Ldlr, Acly, Hmgcr, Acaca, and Scd2) were upregulated at the mRNA level in C2C12 cells transfected with shPARP2 compared to scPARP2-transfected cells. These same lipid metabolism genes were upregulated in the skeletal muscle of PARP2 -/-compared to PARP2 +/+ male mice (Fig. 2B) . Increases in the expression of SREBP1 and SREBP2 were dependent on the induction of their promoters, as suggested by luciferase reporter assays (Fig. 2C) .
We assessed whether changes in the expression of SREBP target genes after silencing of PARP2 are indeed related to changes in SREBP expression. To that end, SREPB1 and
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SREBP2 were silenced in scPARP2 and shPARP2 C2C12 cells (Fig. 2D, Fig. S2 ). Silencing of SREBP1 and SREBP2 abolished the increased expression of HMGCR (Fig. 2E) , pointing toward the involvement of both SREBPs in the PARP2-elicited effects.
SREBP1 and SREBP2 are lipid biosynthetic transcription factors that reside in the endoplasmic reticulum and Golgi, bound to scaffold proteins, when in the presence of sterols [29] . When cholesterol concentrations decrease, SREBPs undergo proteolytic processing and translocate to the nucleus, where they bind to promoters and induce a specific gene set, leading to cholesterol biosynthesis and accumulation [29] . We have observed that increases in SREBP1 and SREBP2 mRNA levels and their downstream target, HMGCR, result in increases in the corresponding proteins in PARP2 knockdown cells and in the gastrocnemius muscle of PARP2 -/-mice (Fig. 3A, Fig. S3A ). Moreover, in cells, the nuclear processed forms of SREBP1 and SREBP2 were also increased upon PARP2 silencing (Fig. 3A, Fig. S3A ), as demonstrated by immunocytochemistry studies showing enhanced accumulation of SREBP1
and SREBP2 in the nucleus (Fig. 3B) .
The question arose whether proteolytic processing of SREBP1 and SREBP2 would be affected by the silencing of PARP2. The expression of the proteins involved in SREBP maturation (Insig1a, Scap, Sp1, Sp2) was unaltered between scPARP2 and shPARP2 C2C12 cells (Fig. 3C) . Similarly, treatment of cells with an inhibitor of the proteolytic processing of SREBPs, betulin [30] , reverted SREBP processing both in scPARP2 and shPARP2 C2C12 cells (Fig. 3D, Fig. S3B ), suggesting that SREBP processing is unaltered when PARP2 is silenced. The enhanced activation of SREBP1 and -2 culminated in increased total cholesterol content in both C2C12 cells transfected with shPARP2 and skeletal muscle of PARP2 -/-male mice (Fig. 3E) .
We next wanted to assess whether muscular cholesterol causes muscular steroidogenesis. We measured the expression of steroidogenic enzymes involved in the conversion of cholesterol to testosterones (anabolic steroids). Out of the genes we assessed, Star, Hsd17b11, Srd5a1, and Srd5a2 were induced in cells or tissues depleted of PARP2 (Fig. 4A) . Increases in the expression of Star and Srd5a1 were dependent on the activation of the promoters of these genes as highlighted by luciferase reporter assays (Fig. 4B) . Star, the commitment enzyme toward steroidogenesis, and 5-α-reductase isoforms, which are at the "output end" of steroidogenesis, were induced in the absence of PARP2. Changes in the expression of the steroidogenic machinery were translated into changes in muscular steroids. Dihydrotestosterone (DHT) levels were higher, whereas androstenedione did not change and testosterone levels were lower in the muscles of the PARP2 -/-mice (Fig 4C) .
Importantly, these changes were restricted to the muscle, as the expression of key PARP2-mediated steroidogenic enzymes remained unchanged in the suprarenal gland and testis of PARP2 -/-mice compared to those of PARP2 +/+ mice (Fig. S4A) . Serum DHT levels showed a A C C E P T E D M A N U S C R I P T 6 minor decrease (Fig. S4B) . Increases in the expression of SREBP-dependent genes and anabolic steroids were absent in PARP2 -/-female mice (Fig. S4C) .
Deletion of PARP2 augmented skeletal muscle contractile function
Testosterones, especially DHT, have an anabolic effect on skeletal muscle [31] , which prompted us to assess muscle strength. Force production was monitored under isometric conditions in single slow and fast twitch skeletal muscle fibers isolated from two mixed-type muscles, the gastrocnemius muscle and the diaphragm, of PARP2 +/+ and PARP2 -/-male mice. Ca 2+ -independent passive force (F passive ) was not statistially different in skeletal myofibers from PARP2 +/+ and PARP2 -/-mice (Fig. 5A) . Ca 2+ -dependent active force (F active ) at submaximal levels of activation and Ca 2+ -activated maximal force production (F max , pCa 4.75)
were higher in both muscles of PARP2 -/-males compared to those of PARP2 +/+ animals, for both fast-and slow-twitch fibers (Fig. 5B) . For the characterization of Ca 2+ sensitivity of isometric force production, F active was normalized to F max for each skeletal muscle fiber (pCa 50 ). The pCa 50 values were significantly higher in fast-twitch fibers of gastrocnemius and diaphragm muscles in PARP2 -/-mice compared to those of PARP2 +/+ mice. (Fig. 5C) . Taken together, the data show that the loss of PARP2 augmented active force production irrespective of muscle fiber type.
Silencing of PARP2 changes lateral diffusion of BODIPY FL-SM
Complex changes in the lipidome may lead to changes in cell membrane structure. To monitor dynamic changes in the plasma membranes, we assessed the lateral diffusion and confinement properties of a fluorescent probe, BODIPY FL-SM (a sphingomyelin-derivative probe). The diffusion coefficient (D) and confinement time ( 0 ) describe the lateral diffusion of the probe and the organization of the membrane, respectively, and can be calculated from the diffusion law graph [32] . We observed increases in the D and in the  0 for the probe ( Fig.   6A-B) , indicating that both the speed and the confinement of the diffusion of the probe were higher in the membranes of PARP2-silenced cells. This strongly suggests that the membrane dynamics of these cells significantly differ from those of the wild type.
Lipids can modulate the expression of PARP2
The results described above point to a possible role for PARP2 in the regulation of lipid homeostasis. Low PARP2 expression or the loss of PARP2 induced a phenotype characterized by lipidome changes and improved muscular contractile function. A recent study showed that α-lipoic acid downregulates PARP2 expression [33] , suggesting that lipidmediated regulatory circles may include changes in PARP2 expression. Lipids frequently exert their expression effects through nuclear receptors; therefore, we assessed the existing
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data on nuclear receptor binding sites to identify transcription factors that could be responsible for the binding of these lipid species. We performed a screening for nuclear receptors that can serve as lipid sensors and translate changes in the lipid environment into gene expression programs. We identified a wide variety of nuclear receptor binding elements (half sites or inverted and direct repeats separated by different base pairs-long spacers) on the PARP2 gene and in its vicinity. Therefore, we selected publicly available ChIP-seq We searched the NCBI GEO database for other lipids that potentially modulate the expression of PARP2. In addition to α-lipoic acid, we identified steroids, such as dexamethasone [34] , medroxyprogesterone acetate, tibolone [35] , and oxandrolone [36] , that can downregulate PARP2 expression and potentially induce changes in lipid homeostasis.
To validate these findings in cell experiments, we treated C2C12 cells with a large set of cholesterol derivatives ( Table 2 ) and subsequently assessed the expression of PARP2. Out of the compounds used in the experiments, MPA, tibolone, LCA, and DCA were capable of downregulating the expression of PARP2 (Fig. 8B ).
Discussion
In this study, we provide evidence that decreased PARP2 expression leads to widespread changes in lipid metabolism. This is achieved through enhancing SREBP1 and 2
transcription. SREBPs are central to the control of a variety of lipid biosynthetic pathways, including lipid desaturation and phospholipid and sterol biosynthesis [37] . PARP2 may induce adaptive responses to dietary/environmental stresses resulting in the maintenance of optimal membrane lipid composition, and profoundly affecting the biophysical properties of biological membranes.
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We demonstrate that changes in lipid metabolism involve alterations in cell membrane lipid composition and synthesis of cholesterol and DHT that, altogether, strengthen muscular output. In addition, we show that some lipids can reduce PARP2 expression and, hence, produce changes in lipid metabolism similarly to the genetic deletion of PARP2.
SREBP1-dependent increases in cholesterol content upon decreased PARP2
expression have already been shown in the liver. Inhibition of PARP2 expression results in beneficial changes to the lipoprotein profile and decreased ABCA1 expression in the liver [14] . The current study provides evidence for the involvement of another tissue, skeletal muscle, in PARP2-elicited changes in lipid metabolism.
In addition to PARP2, other PARPs also play a role in cholesterol homeostasis. The ablation of PARP1 represses cholesterol efflux in macrophages by repressing LXR, resulting in repression of ABCA1 [38] . In hepatocytes, PARP1, together with histone H1.2, is vital for the efficient transcription of microsomal epoxide hydrolase (EPHX1), which facilitates bile acid export [39] . In addition, PARP1 activation has been linked to steroid-evoked changes [40] [41] [42] [43] [44] . A recent study suggests that PARP10 regulates lipid oxidation [45] . Apparently,
PARPs have complex and widespread roles in regulating lipid metabolism.
The current study suggests that certain lipids can repress the expression of PARP2 and, therefore, PARP2 protein levels and activity. The first lipid species shown to inhibit PARP2 expression was α-lipoic acid [33] . Importantly, decreased PARP2 expression via α-lipoic acid had functional consequences, including enhanced SIRT1 activation [33] . Thus, α-lipoic acid may be a viable treatment supplement for obesity and type II diabetes [46] [47] [48] . Hereby, we add a set of cholesterol derivatives (dexamethasone, medroxyprogesterone acetate, tibolone, and oxandrolone) that have similar capabilities. These findings add a new modality to the regulation of PARP2 besides acetylation [49] . Note that PARP1 has lipid activators (7-ketocholesterol and fatty acids) [50, 51] and inhibitors (estrogen) [43] , moreover, PARP1 deletion modulates the levels of several lipid species [52] .
PARP2 has a partial protective effect on oxidative stress-related pathologies [11, 53, 54] and metabolic diseases, like obesity, type II diabetes, and hyperlipidemias [14, 18, 21] , that is due to enhanced SIRT1 expression and the consequent mitochondrial biogenesis. Our current findings show that PARP2 has a role in regulating muscle strength and homeostasis; therefore, the activation of PARP2 can disrupt intramuscular endocrine homeostasis. Finally, as licensed PARP inhibitors block all enzymes in the PARP family, including PARP2 [55] , the phenotype that we described may be a side effect of these inhibitors.
Materials and methods
Chemicals
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All chemicals were from Sigma-Aldrich unless stated otherwise.
Cell culture
PARP2-silenced C2C12 cells were described in [18] . PARP2 knockdown and control clones were maintained over generations. C2C12 cells were cultured in DMEM (4500 mg/L glucose) (Sigma-Aldrich; Saint Louis, MO, USA) with 10% fetal calf serum (FCS). Cells were differentiated in DMEM (4500 mg/L glucose) containing 2% horse serum for 4 days in all experiments, except the luciferase reporter assays.
Animal studies
Homozygous °C. Cages were changed once a week, on the same day. Mice had ad libitum access to food and water (sterilized tap water). The animal facility was overseen by a veterinarian.
Cholesterol determination
Lipids were extracted from muscle and C2C12 cell samples by the Folch method, as described [57] . A cholesterol kit was used for the cholesterol quantitative determination (cholesterol RTU, bioMÉRIEUX; Marcy l'Etoile, France) following the recommendations of the manufacturer and adapted to a microplate format.
SDS-PAGE, Western blotting
Cells and tissues were lysed by RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS, 1%
Nonidet P-40, 1 mM Na 3 VO 3 , 1 mM NaF, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor mixture; pH 8.0), then boiled with 2x
Laemmli sample buffer and merkaptoethanol. Proteins were separated by SDS-PAGE on 8%
acrylamide gels and transferred onto a nitrocellulose membrane (Amersham™ Protran® Supported, GE Healthcare; Chicago, IL, USA). Antibodies used in this study are shown in 
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Cell fractionation
C2C12 cells transfected with scPARP2 or shPARP2 were washed with ice-cold PBS buffer and centrifuged at 4 °C at 100 g for 5 min. Pellets were (re)diluted in 4 volumes of homogenization buffer (0.5 M sucrose and 20 mM HEPES [pH 7.5]; 1 mM EDTA, 1 mM EGTA, protease inhibitors, and 0.5 % Nonidet-P) and were lysed and homogenized by aspirating through a 26-G needle 15 times. Lysates were centrifuged at 4 °C at 5000 g for 10 min. The supernatant was the cytosolic fraction, whereas the pellet was the nuclear fraction.
To prepare the cytoplasmic fraction, the supernatant was centrifuged again at 8000 g at 4 °C 
Immunohistochemistry and confocal microscopy
Monolayer cells were grown on coverslips. Cells were washed with PBS and fixed in icecold methanol (air-dried). After fixation, the cells were rehydrated and permeabilized in 1%
PBS TTX followed by washes with PBS. Cells were incubated in blocking buffer (1 mg/ml BSA/PBS) for an hour at room temperature. After the blocking buffer was removed, cells were incubated with primery antibodies (SREBP1 1:100; SREBP2 1:100) (Santa Cruz; Santa Cruz, CA, USA) in 1 mg/ml BSA/PBS overnight using moist chambers ( Table 4. 
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DNA constructs and luciferase activity measurement
Promoter transactivation was measured using a luciferase reporter assay. Cells were plated onto 6-well plates. Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific;
Walthman, MA, USA) was used for transfection following the recommendations of the manufacturer. Co-transfection was performed with one of the following plasmids (4 µg):
pGL2-SREBP1c-2600luc [59] for the study of the promoter of SREBP1, pKM2L-phSREBP2
(from the RIKEN Bioresource Center, Japan) for the study of the promoter of SREBP2, p-966
Star/hGH (generous gift from Barabara J. Clark; University of Louisville; Louisville, KY, USA) [60] for the study of the promoter of StAR, p-Luc-GW-Srd5a2 (-1500/+107) (generous gift from Timothy Osborne; Sanford-Burnham Medical Research Institute; Orlando, FL, USA) [61] for the study of the promoter of srd5a and 2 µg β-galactosidase expression plasmid (pCMVβgal). Luciferase activity was measured by a Victor 3 multilabel plate reader and normalized to β-galactosidase activity. 
Microarray experiments and validation
Total RNA was extracted, using an RNeasy Mini Kit (Qiagen; Hilden, Germany), from C2C12 cells transfected with scPARP2 and shPARP2. RNA quality was assessed using Agilent Bioanalyser 2100 (Agilent Technologies; Santa Clara, CA, USA). The global expression pattern was analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST array.
Microarray experiments were performed as in [14] . Gene expressions profiles were validated by RT-qPCR as described later.
Lipid extraction and mass spectrometry
The solvents used for extraction and for mass spectrometry analyses were of liquid chromatographic grade (Merck; Darmstadt, Germany) and Optima LCMS grade (Thermo Fisher Scientific; Bremen, Germany). Lipid standards were obtained from Avanti Polar Lipids (Alabaster, AL, USA). All other chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) and were of the best available grade. 
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was transferred into a new Eppendorf tube and stored at −20 °C. For muscle samples, tissues were weighed and disrupted in water using a bullet blender homogenizer (Bullet Blender Gold, Next Advance; Location) in the presence of stainless steel beads (0.9-2 mm) at speed 10 for 7 min at 4 °C. Lipid extraction was carried out from a portion of the homogenate (ca. 10 µL corresponding to 2 mg w/w) in a similar fashion as for cell samples.
Mass spectrometric analyses were performed on a LTQ-Orbitrap Elite instrument (Thermo Fisher Scientific; Bremen, Germany) equipped with a robotic nanoflow ion source (TriVersa NanoMate; Advion BioSciences; Ithaca, NY, USA) as described in [62] . Orthogonal PLS-DA analyses of lipidomics datasets were performed using MetaboAnalyst [63] .
RT-qPCR
Total RNA was isolated by Extrazol ready-to-use reagent (Blirt S. A.; Gdańsk, Poland).
cDNA synthesis and RT-qPCR were performed as described in [14] . Expression was normalized to a geometric mean of 18S, cyclophilin or Gapdh. Primers are listed in Table 3 .
Mechanical measurements in single permeabilized skeletal myofiber preparations
Gastrocnemius and diaphragm muscle tissue were obtained from PARP2 +/+ and PARP2 concentrations were prepared by mixing activating and relaxing solutions (pCa = 5.4-7.0).
Active force (F active ) and Ca 2+ -sensitivity to force production (pCa 50 ) were determined in activating solutions with different Ca 2+ concentrations. When active muscle force reached its
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13 maximum, a quick release-restretch maneuver (30 ms) was applied in activating solution.
Due to this maneuver, force first dropped from the peak isometric level to 0 (total peak isometric force, F total ) and then it started to redevelop. 
Muscular steroid hormone extraction and determination
Steroid extraction was performed similarly to [64] . DHT, testosterone, and androstenedione were measured by an RIA kit (Beckman Coulter; Brea, CA, USA).
Testosterone and androstenedione were determined from whole skeletal muscle of a mouse.
For the measurement of DHT, a pool of gastrocnemius muscle was used from PARP2 wildtype and from PARP2 knockout mice; hence, we cannot determine the biological error.
ImFCS
Cells were seeded into glass bottom dishes (MatTek Corporation; City, MA, USA) a day before the experiments. After labeling the cells with fluorescent lipid probe (BODIPY FL C5-sphingomyelin; Molecular Probes; Eugene, OR, USA) for 8 min at 37 °C, cells were washed three times with the culture media. The measurements were performed in culture media without phenol red, in a POC-R cell cultivation system (Zeiss; Jena, Germany). This system incorporates a controlled objective heater and CO 2 /air gas chamber. Objective-type TIRF illumination was used to achieve the thinnest excited sample volume, with a high numerical aperture objective (alpha Plan-FLUAR 100; Zeiss). The data were acquired using a ProEM512 EMCCD camera (Princton Instruments; Trenton, NJ, USA) with a 3-ms effective exposure time and a 20 × 40 pixel acquisition area per measurement (pixel size = 0.16 µm).
The ImFCS plugin for ImageJ software was used for data evaluation (http://www.dbs.nus.edu.sg/lab/BFL/imfcs_image_j_plugin.html). Detailed data analysis is described in [62] .
Chip-seq reanalysis
We investigated 32 publicly available ChIP-seq data in nine different human and mouse cell types (GEO identifiers and references are in Table 5 Raw sequence data were aligned to the mm10 reference genome assembly by using the Burrows-Wheeler Alignment (BWA) tool (v0.7.10) [65] . BAM files were generated by SAM tools (v0.1.19) [66] , and BEDGRAPH files were created by the makeUCSCfile of Hypergeometric Optimization of Motif EnRichment (HOMER) tool (v4.2) [67] . Peaks were predicted with MACS2 [68] , and coverage files were also created by HOMER.
The equivalent DNA sequences of the Vitamin D response element (VDRE) at human PARP1 gene promoter could be identified in 37 different species based on the Comparative Genomics data sets of Ensembl database (Archive Ensembl 75: GRCh17.p13). Sequence of the VDRE ±10 base pairs was visualized by using BioEdit Sequence Alignment Editor (v7.0.5.3) [69] .
Database screening
The GEO (profiles) database of the NCBI was screened for PARP2+steroid and PARP2+lipid keywords.
Data availability
The primary data of the present manuscript are available at https://figshare.com/s/3e7866c3ce9db7c4df88. The microarray dataset has been uploaded to the Geo database of NCBI at GSE108737.
Statistical analysis
For the comparison of two groups, we used the two-tailed, unpaired Student's t-test. p values smaller than 0.05 were considered significant. Significance levels were given in the
figure captions, actual p values can be found in the primary dataset available online (https://figshare.com/s/3e7866c3ce9db7c4df88). Actual p values are given for those comparisons, where p is slightly higher than 0.05. A. Vitamin D receptor (VDR) peaks were identified in available ChIP-seq data as described.
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B. VDREs were identified on the promoter of PARP2 in different species. B. C2C12 cells were treated with the lipid species in the concentrations indicated for 48 h; then PARP2 levels were assessed by Western blotting (n = 2).
The two-tailed, unpaired Student's t-test was used for comparisons. Data are expressed as mean ± SEM; * and ** represent statistical significance at p = 0.05 or 0.01 between vehicle and drug-treated C2C12 cells, respectively. Abbreviations are in Table 2 . 
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A C C E P T E D M A N U S C R I P T 25 2. In PARP2 knockout mice SREBP1 and SREBP2 is overexpressed in skeletal muscle leading to higher muscular cholesterol biosynthesis.
3. Higher muscular cholesterol is shunted towards muscular dihydrotestoesterone synthesis, but is not translated into systemic increases in dihydrotestosterone levels.
4. The muscles from PARP2 knockout mice are stronger as compared to the ones derived from wild type littermates.
5. The expression of PARP2 is regulated by cholesterol derivatives.
Figure 1 
